Could a nerve drug boost GIST treatment? new trial launches

NCT ID NCT07171203

First seen Sep 30, 2025 · Last updated May 14, 2026 · Updated 30 times

Summary

This early-phase study tests adding fampridine to standard imatinib (Gleevec) in people with a specific type of gastrointestinal stromal tumor (GIST) that has a KIT gene mutation. The goal is to find the safest dose of the combination and see if it shrinks tumors before surgery. About 18 adults who have not had prior treatment will take the drugs for at least two months before their operation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California, San Diego

    RECRUITING

    La Jolla, California, 92093, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.